Special Interest Network on Infectious Diseases

HIV and congenital rubella has the corner been turned?

Speaker: Pat Tookey

Duration: 0:20:09
Learning objectives: At the end of the video, viewers will: (1) understand the challenges and benefits of long term national surveillance of two very different infections in the context of changing management strategies and epidemiology; (2) learn the benefits of the parallel obstetric and paediatric HIV reporting systems; and (3) understand the continued importance of national surveillance even though there are only one or two congenital rubella cases currently reported each year in the UK.

Pneumococcal & Meningococcal Meningitis - S2

Speaker: Matthew Snape

Duration: 0:30:05 

Interactive Case Series The CoMO Change Equation Part 2

Speaker: Catherine Weil-Olivier

Duration: 0:04:19

Pneumococcal & Meningococcal Meningitis - S1

Speaker: Catherine Weil Olivier

Duration: 0:32:30

Pneumococcal & Meningococcal Meningitis - S3

Speaker: Jamie Findlow

Duration: 0:26:10

The latest recommendations and guidelines for the meningitis booster for adolescents

Speaker: George Syrogiannopoulos

Duration: 0:21:16
Learning objectives: At the end of the video, viewers will: (1) Learn that the highest incidence of meningococcal disease occurs in children under 5 years of age, but a second peak occurs in adolescents and higher case fatality rates are generally reported in this age group. (2) Understand that children are being immunized in infancy with the meningococcal serogroup C conjugate vaccine (3) Learn that as children get older the protective antibody titres against meningococcal serogroup C are waning. (4) Adolescents need to receive a booster dose and currently a quadrivalent meningococcal conjugate vaccine (MenACYW), offering coverage against serogroup C, as well against serogroups A, Y and W135, is recommended.

Read more

Meningitis surveillance and vaccination coverage updates. Meningococcal B vaccine introduction in Europe

Speaker: George Syrogiannopoulos

Duration: 0:24:09
Learning objectives: At the end of the video, viewers will: (1) Learn that currently Neisseria meningitidis (meningococcus) and pneumococcus are the two most common etiologic agents of bacterial meningitis in Europe. (2) Understand the overall burden of meningococcal disease and the role of the different meningococcal serogroups with serogroup B being the predominant one in Europe. (3)Learn that recently, two new meningococcal serogroup B protein vaccines have been available. (4)Learn that MenB-4C vaccine has been approved in Europe and universal vaccination of young infants has been initiated in the UK. (5) Understand the accumulating data on the immunogenicity, safety and effectiveness of MenB-4C vaccine in different areas of the world.

get updates